Available Technologies


Project TitleImmune Response-Related Genes Associated with Clinical Outcomes of anti-EGFR Therapy
Track Code2016-114
Short Description
Tagscolorectal cancer, anti-EGFR therapy, clinical outcome marker, pharmacogenomics, oncology
Posted DateMar 10, 2017 12:55 PM

Market Opportunity

Anti-EGFR (epidermal growth factor receptor) therapies, including monoclonal antibodies-based therapies have demonstrated activity in a variety of tumor types including metastatic colorectal cancer (mCRC). Methods to select patients to receive antibody-based anti-EGFR therapy based on gene expression levels would avoid administration of unnecessary treatment, mitigate toxicity and increase treatment efficacy.

USC Solution

USC researchers have developed a method for identifying colorectal cancer patients suitable for an anti-EGFR therapy based on the determination of the intra-tumoral expression level of certain immune-related genes in a cell or tissue sample. This such method is able to identify subtypes of patients with more favorable clinical outcomes of first-line treatment for metastatic colorectal cancer (mCRC). Favorable clinical outcomes include longer overall survival (OS) and progression-free survival (PFS).

Value Proposition

  • Able to identify patients more likely to respond to anti-EGFR therapy
  • Improved clinical outcomes (PFS and OS)
  • Utilizes standard molecular techniques


  • Colorectal cancer treatment
  • Identification of patients suitable for anti-EGFR therapy

Stage of Development

  • More than 2,500 genes in 77 patient samples undergoing first-line anti-EGFR treatment have been analyzed

Intellectual Property


Patent pending

Key Publication:

Publication pending

Contact Information

Camilo Ansarah-Sobrinho, Licensing Associate, Life Sciences

USC Stevens Center for Innovation

(213) 821-6071



File Name Description
NCD 2016-114 - Immune Response-Related Genes Associated with Clinical Outcomes of anti-EGFR Therapy.pdf None Download